April 2025 in “Archives of Dermatological Research” The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.
October 2024 in “Journal of Drugs in Dermatology” This study found that a combination of topical finasteride 0.25% with minoxidil 5% was more effective than using topical minoxidil 5% alone for treating male pattern androgenic alopecia over a 12-week period.
October 2023 in “Journal of Cosmetic Dermatology” In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
March 2023 in “International Journal of Trichology” This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.
13 citations
,
February 2022 in “JAMA Dermatology” This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
47 citations
,
December 2020 in “Journal of the European Academy of Dermatology and Venereology” This article reviews the classification, diagnosis, and management of hair disorders, emphasizing the role of trichoscopy and early diagnosis for effective treatment but reports no new clinical findings.
11 citations
,
June 2020 in “Dermatologic Therapy” This study suggests that combination therapies including minoxidil with either finasteride, low-level laser light therapy, or microneedling are more effective than minoxidil alone for treating androgenetic alopecia.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.
117 citations
,
August 2019 in “Drug Design Development and Therapy” This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.
43 citations
,
July 2018 in “Journal of The European Academy of Dermatology and Venereology” This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.
46 citations
,
February 2016 in “Experimental Dermatology” This review discusses the genetic research developments in androgenetic alopecia, reporting no new clinical results, and highlights the potential for discovering novel therapeutic targets.
5 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.
6 citations
,
October 2012 in “PubMed” This study found that while the combination therapy of 3% minoxidil and 0.1% finasteride lotion showed greater improvement in global photographic assessments for androgenetic alopecia, hair counts did not differ significantly from minoxidil alone.
134 citations
,
August 2012 in “The Journal of Clinical Psychiatry” This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.
215 citations
,
November 2006 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
